Revisiting RAAS blockade in CKD with newer potassium-binding drugs

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Proteinuric chronic kidney disease (CKD) guidelines recommend renin angiotensin aldosterone system (RAAS) inhibitors for renoprotection.
• Hyperkalemia is a significant limitation, often preventing optimal RAAS inhibitor dosing or leading to discontinuation.
• This limits the renoprotective benefits for many CKD patients.

Purpose of the Study:

• To review the role of novel potassium binders in managing hyperkalemia in CKD patients on RAAS inhibitors.
• To explore the potential of these agents to improve RAAS inhibitor tolerability and efficacy.

Main Methods:

• Review of existing randomized trials and clinical data on patiromer and sodium zirconium cyclosilicate (ZS-9).
• Analysis of the impact of these potassium binders on serum potassium levels and RAAS inhibitor adherence.
• Assessment of the potential for these therapies to overcome hyperkalemia barriers.

Main Results:

• Patiromer and ZS-9 effectively reduce serum potassium and maintain normokalemia in CKD patients on RAAS inhibitors.
• These agents demonstrate a favorable safety profile for long-term use.
• Evidence suggests they can facilitate sustained RAAS blockade.

Conclusions:

• Novel potassium binders show promise in mitigating hyperkalemia associated with RAAS inhibition in proteinuric CKD.
• These therapies may enhance the tolerability and effectiveness of RAAS inhibitors, potentially improving renoprotective outcomes.
• Further randomized trials are needed to confirm these benefits in proteinuric CKD patients.